FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286293842> ?p ?o ?g. }

• W4286293842 endingPage "9538" @default.
• W4286293842 startingPage "9538" @default.
• W4286293842 abstract "9538 Background: LBL007 is a novel, fully human IgG4 monoclonal antibody targeting human Lymphocyte-activation gene3 (LAG-3). Dual inhibition of anti-programmed cell death protein 1 (PD-1) and LAG-3 is anticipated to synergistically increase immune response against tumor growth. Here we report the preliminary safety and efficacy of LBL-007 in combination with Toripalimab (an anti-PD-1 antibody has approved for treatment of melanoma in China) in patients (pts) with unresectable or metastatic melanoma. Methods: Pts with unresectable or metastatic melanoma with or without prior anti-PD-(L)1 therapy were enrolled. This trial comprised 2 parts, namely part 1 (dose escalation), pts received LBL-007 (0.25/1/3/6 mg/kg) /Toripalimab (3 mg/kg) both i.v., Q2W; and part 2 (expansion), pts received LBL-007 (3/6 mg/kg)/Toripalimab (3 mg/kg) both i.v., Q2W. The primary objective was safety, the second objectives included pharmacokinetics, pharmacodynamics and efficacy (per RECIST 1.1). Results: By Jan 2022, 37 pts (15 [40.5%] male, median age 59 [range 31-74] years, 9 pts [24.3%] with baseline LDH elevation, 18 [48.6%] with acral, 12 [32.4%] mucosal, 5 [13.5%] nonacral cutaneous, 2 [5.4%] primary site unknown) were enrolled, with 17 in part 1 and 20 in part 2. No dose-limiting toxicity was observed in part 1, and the MTD was not reached. Of all 37 pts, the most common treatment-emergent adverse events (TEAEs) included anemia (24.3%), creatine phosphokinase elevation (24.3%), hypothyroidism (21.6%), and aspartate aminotransferase elevation (21.6%). For 32 radiologically evaluable pts, ORR was 12.5%, DCR was 53.1%. In a preplanned subtype-specific analysis in anti-PD-(L)1 treatment-naïve pts, ORR was 27.3 % vs. 0%, and DCR was 81.8% vs. 50.0% in acral and mucosal melanoma subtypes, respectively. For anti-PD-(L)1-resistant pts (n = 11), DCR was 18.2%. Conclusions: LBL007/Toripalimab combination is well tolerated and promising efficacy in pts with unresectable or metastatic melanoma, especially in the acral type without prior anti-PD-(L)1 therapy. Clinical trial information: NCT04640545." @default.
• W4286293842 created "2022-07-21" @default.
• W4286293842 creator A5005335792 @default.
• W4286293842 creator A5009884211 @default.
• W4286293842 creator A5011275476 @default.
• W4286293842 creator A5018372804 @default.
• W4286293842 creator A5034584841 @default.
• W4286293842 creator A5047774145 @default.
• W4286293842 creator A5048379858 @default.
• W4286293842 creator A5056437521 @default.
• W4286293842 creator A5058845432 @default.
• W4286293842 creator A5060306679 @default.
• W4286293842 creator A5077322975 @default.
• W4286293842 date "2022-06-01" @default.
• W4286293842 modified "2023-09-27" @default.
• W4286293842 title "Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase Ⅰ, open-label, multicenter, dose escalation/expansion study." @default.
• W4286293842 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.9538" @default.
• W4286293842 hasPublicationYear "2022" @default.
• W4286293842 type Work @default.
• W4286293842 citedByCount "1" @default.
• W4286293842 countsByYear W42862938422023 @default.
• W4286293842 crossrefType "journal-article" @default.
• W4286293842 hasAuthorship W4286293842A5005335792 @default.
• W4286293842 hasAuthorship W4286293842A5009884211 @default.
• W4286293842 hasAuthorship W4286293842A5011275476 @default.
• W4286293842 hasAuthorship W4286293842A5018372804 @default.
• W4286293842 hasAuthorship W4286293842A5034584841 @default.
• W4286293842 hasAuthorship W4286293842A5047774145 @default.
• W4286293842 hasAuthorship W4286293842A5048379858 @default.
• W4286293842 hasAuthorship W4286293842A5056437521 @default.
• W4286293842 hasAuthorship W4286293842A5058845432 @default.
• W4286293842 hasAuthorship W4286293842A5060306679 @default.
• W4286293842 hasAuthorship W4286293842A5077322975 @default.
• W4286293842 hasConcept C111113717 @default.
• W4286293842 hasConcept C112705442 @default.
• W4286293842 hasConcept C126322002 @default.
• W4286293842 hasConcept C143998085 @default.
• W4286293842 hasConcept C197934379 @default.
• W4286293842 hasConcept C2777658100 @default.
• W4286293842 hasConcept C2778248108 @default.
• W4286293842 hasConcept C29730261 @default.
• W4286293842 hasConcept C31760486 @default.
• W4286293842 hasConcept C502942594 @default.
• W4286293842 hasConcept C71924100 @default.
• W4286293842 hasConcept C90924648 @default.
• W4286293842 hasConceptScore W4286293842C111113717 @default.
• W4286293842 hasConceptScore W4286293842C112705442 @default.
• W4286293842 hasConceptScore W4286293842C126322002 @default.
• W4286293842 hasConceptScore W4286293842C143998085 @default.
• W4286293842 hasConceptScore W4286293842C197934379 @default.
• W4286293842 hasConceptScore W4286293842C2777658100 @default.
• W4286293842 hasConceptScore W4286293842C2778248108 @default.
• W4286293842 hasConceptScore W4286293842C29730261 @default.
• W4286293842 hasConceptScore W4286293842C31760486 @default.
• W4286293842 hasConceptScore W4286293842C502942594 @default.
• W4286293842 hasConceptScore W4286293842C71924100 @default.
• W4286293842 hasConceptScore W4286293842C90924648 @default.
• W4286293842 hasIssue "16_suppl" @default.
• W4286293842 hasLocation W42862938421 @default.
• W4286293842 hasOpenAccess W4286293842 @default.
• W4286293842 hasPrimaryLocation W42862938421 @default.
• W4286293842 hasRelatedWork W1541406077 @default.
• W4286293842 hasRelatedWork W1976341559 @default.
• W4286293842 hasRelatedWork W2037616672 @default.
• W4286293842 hasRelatedWork W2076177612 @default.
• W4286293842 hasRelatedWork W2130167599 @default.
• W4286293842 hasRelatedWork W2194222775 @default.
• W4286293842 hasRelatedWork W2252729110 @default.
• W4286293842 hasRelatedWork W2806504080 @default.
• W4286293842 hasRelatedWork W2895359474 @default.
• W4286293842 hasRelatedWork W4306946079 @default.
• W4286293842 hasVolume "40" @default.
• W4286293842 isParatext "false" @default.
• W4286293842 isRetracted "false" @default.
• W4286293842 workType "article" @default.